We also constructed dichotomous variables that measure whether the beneficiary had been treated for the particular study condition in prior years: no prior episodes in 2004 and 2005, episodes in both prior years, or in one or the other prior year.
We designated hospital volume as the number of eligible patients treated for the current study and categorized into quartiles (very low, low, high, and very high).
If both eyes of a subject were eligible at baseline, both eyes were treated for the duration of study.
To quantify this effect, we calculated the expected number of semi-urgent slots treated for the example in the case study where s* = 13.
FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; SINGLE, study group treated for the first 2 years with one disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; RA, rheumatoid arthritis; SINGLE, study group treated for the first 2 years with one disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.
A potential problem with the current study was that 36.2% of the patients treated for IE during the study period (71/196) lacked stored blood samples.
This paper presents the protocol of a RCT to investigate the presence of borderline personality features in patients treated for BD (study part 1) and the effectiveness of STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD compared to TAU in patients with BD and comorbid borderline personality features (study part 2).
This study gives no information about the prevalence of failing treatment because the total number of patients treated for GERD in the study period is unknown, a large proportion did not answer the written inquiry or was unwilling to participate, and patients with mild or intermittent symptoms were excluded.
The proportion of patients treated for hypertension before the study run-in phase (40% with angiotensin converting enzyme inhibitors, 20% with an angiotensin receptor blocker, and 21% with combination therapy including a calcium antagonist or diuretic) had increased to 66.9%, with little difference between the groups.
